In summary, based on the PLCO trial, the main purpose of this study is to determine the PSA reference level for population-based PCa screening and then to determine the optimal subgroup-specific progression indicators and their subgroup-specific cut-off values under the setting of population-based screening. This evidence concerns the gene KLK3 and posterior cortical atrophy.